Neurocrine Biosciences, Inc. NBIX
Set alert
At close · Nov 2
After hours · Nov 2, 6:21 PM ET
- YTD
- +2.48%
- 1 year
- +1.49%
- Open
- 145.70
- Prev close
- 146.10
- Mkt cap
- 14.77B
- Vol
- 1.99M
- Avg vol
- 1.24M
- EPS
- 6.82
- P/E
- 21.31
- Div yield
- 0.00%
More statistics
- Low
- 143.75
- High
- 147.57
- Forward P/E
- 12.14
- Beta
- 0.33
- Short ratio
- 4.41
- Inst. own
- 104.46%
- Dividend
- 0.00
- Ex-div date
- Dec 28, 1995
- Earnings
- Nov 2, 2026
- 50-d avg
- 146.63
- 200-d avg
- 147.38
- 1y target
- 206.22
1M chart
Events in this range
- Oct 12, 2026Rating: BMO Capital · Market Perform → Market Perform
- Oct 16, 2026Rating: Needham · Buy → Buy
- Nov 2, 2026Earnings: —; estimate 1.91; surprise —%
Signals (6)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 20, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 20, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 14, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 12, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 9, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 8, 2026 | 3 weeks ago |
Key statistics
- Market cap
- 14.77B
- Enterprise value
- 14.92B
- Trailing P/E
- 21.31
- Forward P/E
- 12.14
- PEG ratio
- 0.30
- Price / sales
- 4.38
- Price / book
- 4.00
- EPS (TTM)
- 6.82
- Beta
- 0.33
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 20.91%
- Revenue (TTM)
- 3.37B
- Revenue growth
- 39.50%
- Free cash flow
- 638.24M
- Total cash
- 389.80M
- Total debt
- 461.60M
- Return on equity
- 22.09%
- Shares outstanding
- 101.65M
- Short % of float
- 8.24%
- 50-day average
- 146.63
- 200-day average
- 147.38
Analyst view
Consensus: strong buy
- Target (low)
- 150.00
- Target (mean)
- 206.22
- Target (high)
- 253.00
- Strong buy4
- Buy21
- Hold4
- Sell0
- Strong sell0
Next earnings
Nov 2, 2026
Expected Nov 2, 2026. Consensus EPS estimate 2.75.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 2, 2026 | Sep 30, 2026 | 1.91 | — | — | — |
| Jul 30, 2026 | Jun 30, 2026 | 1.85 | 2.85 | +1.00 | +54.05% |
| May 5, 2026 | Mar 31, 2026 | 1.22 | 1.91 | +0.69 | +56.56% |
| Feb 11, 2026 | Dec 31, 2025 | 1.80 | 1.88 | +0.08 | +4.44% |
| Oct 28, 2025 | Sep 30, 2025 | 1.58 | 2.04 | +0.46 | +29.11% |
| Jul 30, 2025 | Jun 30, 2025 | 0.98 | 1.06 | +0.08 | +8.16% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 16, 2026 | Needham | reit | Buy | Buy |
| Oct 12, 2026 | BMO Capital | main | Market Perform | Market Perform |
| Sep 29, 2026 | UBS | main | Buy | Buy |
| Sep 11, 2026 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
| Sep 8, 2026 | RBC Capital | reit | Outperform | Outperform |
| Sep 3, 2026 | Citigroup | main | Buy | Buy |
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- neurocrine.com
News
- Neurocrine Biosciences Raises FY 2026 INGREZZA Net Product Sales Guidance from $2.825B-$2.875B to $2.900B-$2.925B
- Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results
- Neurocrine Biosciences Q3 Adj. EPS $3.29 Beats $1.91 Estimate, Sales $1.119B Beat $1.043B Estimate
- Here's Why Neurocrine Biosciences (NBIX) is a Strong Value Stock
- Apple, Palantir On Deck Monday As AI Demand, iPhone Growth Face Test
- Here's Why Neurocrine Biosciences (NBIX) is a Strong Growth Stock
- Neurocrine Biosciences Launches Interactive Educational Resources to Support Clinical Learning in Classic Congenital Adrenal Hyperplasia
- Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
- Neurocrine Biosciences Identifies Clinically Meaningful Health Improvement Threshold For INGREZZA In Tardive Dyskinesia Patients
- Neurocrine Biosciences Presents New Analysis Establishing Benchmark for Clinically Meaningful Change in Overall Health Reported by Patients with Tardive Dyskinesia
Your note
Sign in to keep a note on NBIX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ABERNETHY MATTHEW C | Chief Financial Officer | Sale | Sep 13, 2026 | 42,808 |
| BENEVICH ERIC S. | Officer | Stock Award(Grant) | Sep 10, 2026 | 67,297 |
| COOKE JULIE SMITH | Officer | Stock Award(Grant) | Sep 10, 2026 | 24,025 |
| GANO KYLE W | Chief Executive Officer | Stock Award(Grant) | Sep 10, 2026 | 154,728 |
| GORMAN KEVIN CHARLES | Director | Stock Award(Grant) | Sep 10, 2026 | 517,797 |
| LIPPOLDT DARIN M | Officer | Stock Award(Grant) | Sep 10, 2026 | 56,793 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 13.49% | 13,711,607 | 1.99B | Jun 29, 2026 |
| JPMORGAN CHASE & CO | 6.29% | 6,398,674 | 930.05M | Jun 29, 2026 |
| Dodge & Cox Inc. | 5.49% | 5,584,707 | 811.74M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 4.89% | 4,974,083 | 722.98M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.47% | 4,545,339 | 660.67M | Jun 29, 2026 |
| State Street Corporation | 4.31% | 4,385,598 | 637.45M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Dodge & Cox Funds-Dodge & Cox Stock Fund | 3.90% | 3,964,000 | 576.17M | Jun 29, 2026 |
| iShares Trust-iShares Core S&P Mid-Cap ETF | 3.56% | 3,620,760 | 526.28M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.14% | 3,193,267 | 464.14M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.27% | 2,304,996 | 335.03M | Jun 29, 2026 |
| J.P. Morgan Mutual Fd. Investment TRT-JPMorgan Growth Advantage Fd. | 1.34% | 1,358,475 | 197.45M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.31% | 1,329,829 | 193.29M | Jun 29, 2026 |